Rapport Therapeutics, Inc. (RAPP)

Over the past six months, Rapport Therapeutics' stock price has been impacted by several events. Positive Phase 2a results for RAP-219 in focal onset seizures demonstrated robust activity and seizure freedom. Financial reports and business updates highlighted a strong cash position expected to fund operations into the second half of 2029. The company announced the accelerated initiation of its RAP-219 Phase 3 program for focal onset seizures. A strategic collaboration with Tenacia Biotechnology was announced for the development and commercialization of RAP-219 in Greater China. The company participated in investor conferences, influencing investor sentiment. Company insiders sold 41,206 shares of company stock worth $1,151,091. The share price increased by 217.97% between April 2, 2025, and April 1, 2026, with a 28.9% return over the past six months.

As a clinical-stage biopharmaceutical company, Rapport Therapeutics, Inc. is focused on the discovery and development of new medicines that are still in various stages of clinical trials. Its products are not yet commercialized and available on the market; therefore, there is no information available regarding demand seasonality for Rapport Therapeutics' products and services.

Rapport Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing precision small molecule medicines for central nervous system disorders. The company operates in the Biotechnology & Medical Research sector and the Pharmaceutical Products industry, utilizing its RAP technology platform to develop CNS drugs specific to receptor variants and neuroanatomical regions. Their lead product candidate, RAP-219, is being developed for focal onset epilepsy, peripheral neuropathic pain, and bipolar disorder, with additional discovery-stage programs targeting chronic pain and hearing disorders.

Rapport Therapeutics, Inc. has its principal executive offices in Boston, Massachusetts, and operations in San Diego, California. The company has expanded its reach through a strategic collaboration with Tenacia Biotechnology (Hong Kong) Co., Ltd. for the development and commercialization of RAP-219 in Greater China.

Rapport Therapeutics has maintained a positive brand reputation over the past year, particularly within the financial and biotech analyst communities. The company has received a consensus "Buy" rating from analysts, with an average rating score of 3.00. Raymond James Financial upgraded Rapport Therapeutics to a "strong-buy" rating in April 2026, and other firms have also issued "buy" or "market outperform" ratings and raised price targets. No specific major negative events or controversies significantly impacted Rapport Therapeutics' brand reputation in the past year.

Rapport Therapeutics, Inc. has a significant institutional ownership presence, with 141 institutional owners and shareholders holding a total of 40,243,566 shares, accounting for approximately 100.14% of the company. Individuals hold about 4.6%. Major institutional owners include Fmr Llc, Arch Venture Corp, Capital International Investors, Goldman Sachs Group Inc, BlackRock, Inc., Sofinnova Investments, Inc., Vanguard Group Inc, Johnson & Johnson, Baker Bros. Advisors Lp, and Vestal Point Capital, LP. Third Rock Ventures V LP is the largest individual shareholder, owning 16.96% of the company. Insiders collectively own 13.57% of the company's stock.